MX2020006658A - Tratamiento de hipoglucemia inducida por el ejercicio en la diabetes tipo 1 y tipo 2 en la que se usa insulina. - Google Patents
Tratamiento de hipoglucemia inducida por el ejercicio en la diabetes tipo 1 y tipo 2 en la que se usa insulina.Info
- Publication number
- MX2020006658A MX2020006658A MX2020006658A MX2020006658A MX2020006658A MX 2020006658 A MX2020006658 A MX 2020006658A MX 2020006658 A MX2020006658 A MX 2020006658A MX 2020006658 A MX2020006658 A MX 2020006658A MX 2020006658 A MX2020006658 A MX 2020006658A
- Authority
- MX
- Mexico
- Prior art keywords
- type
- exercise
- insulin
- diabetes
- treatment
- Prior art date
Links
- 208000013016 Hypoglycemia Diseases 0.000 title abstract 2
- 230000002218 hypoglycaemic effect Effects 0.000 title abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
- 102000004877 Insulin Human genes 0.000 title 1
- 108090001061 Insulin Proteins 0.000 title 1
- 229940125396 insulin Drugs 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 4
- 102000051325 Glucagon Human genes 0.000 abstract 2
- 108060003199 Glucagon Proteins 0.000 abstract 2
- 229960004666 glucagon Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 1
- 230000000977 initiatory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Ciertas modalidades se refieren a los métodos para el tratamiento, la mitigación, o la prevención de la hipoglucemia inducida por el ejercicio o asociada con el ejercicio, los cuales comprenden la administración a un sujeto que lo necesite, de una formulación o formulaciones de glucagon o de un análogo de glucagon en una cantidad eficaz para el tratamiento, la mitigación, o la prevención de la afección. Al sujeto se le puede administrar una composición de glucagon o de un análogo de glucagon de 1, 5, 10, 15 a 20, 25, 30 minutos antes del inicio del ejercicio.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762609964P | 2017-12-22 | 2017-12-22 | |
| PCT/US2018/067294 WO2019126753A1 (en) | 2017-12-22 | 2018-12-21 | Treatment of exercise-induced hypoglycemia in type 1 and insulin using type 2 diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020006658A true MX2020006658A (es) | 2020-11-06 |
Family
ID=65139204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020006658A MX2020006658A (es) | 2017-12-22 | 2018-12-21 | Tratamiento de hipoglucemia inducida por el ejercicio en la diabetes tipo 1 y tipo 2 en la que se usa insulina. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20210008170A1 (es) |
| EP (1) | EP3727427A1 (es) |
| JP (1) | JP2021506933A (es) |
| KR (1) | KR20200103029A (es) |
| CN (1) | CN111565740A (es) |
| AU (1) | AU2018388417C1 (es) |
| BR (1) | BR112020012268A2 (es) |
| MX (1) | MX2020006658A (es) |
| WO (1) | WO2019126753A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020006658A (es) | 2017-12-22 | 2020-11-06 | Xeris Pharmaceuticals Inc | Tratamiento de hipoglucemia inducida por el ejercicio en la diabetes tipo 1 y tipo 2 en la que se usa insulina. |
| EP3876908A4 (en) | 2018-11-08 | 2022-07-27 | The Governing Council Of The University Of Toronto | COMPOSITION AND DEVICE FOR THE PREVENTION OF HYPOGLYCEMIA AND USE THEREOF |
| JP7689499B2 (ja) * | 2019-05-31 | 2025-06-06 | ゼリス ファーマシューティカルズ インコーポレイテッド | 非プロトン性極性溶媒中の安定な治療用組成物およびその製造方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012225268B2 (en) | 2011-03-10 | 2016-10-20 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of peptide drugs |
| WO2013086292A1 (en) * | 2011-12-09 | 2013-06-13 | Enject, Inc. | Glucagon formulations |
| US9018162B2 (en) * | 2013-02-06 | 2015-04-28 | Xeris Pharmaceuticals, Inc. | Methods for rapidly treating severe hypoglycemia |
| KR102327754B1 (ko) * | 2014-02-06 | 2021-11-17 | 엑스에리스 파머수티클스, 인크. | 안정한 펩티드 제형물 및 제조 방법 |
| CN107106659B (zh) | 2014-10-27 | 2022-07-08 | 莱迪杜德制药公司 | 肠胃外胰高血糖素制剂 |
| WO2016196976A1 (en) * | 2015-06-04 | 2016-12-08 | Xeris Pharmaceuticals, Inc. | Glucagon delivery apparatuses and related methods |
| US9649364B2 (en) * | 2015-09-25 | 2017-05-16 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic formulations in aprotic polar solvents |
| EP3307295A1 (en) * | 2015-06-10 | 2018-04-18 | Xeris Pharmaceuticals, Inc. | Use of low dose glucagon |
| MX2020006658A (es) | 2017-12-22 | 2020-11-06 | Xeris Pharmaceuticals Inc | Tratamiento de hipoglucemia inducida por el ejercicio en la diabetes tipo 1 y tipo 2 en la que se usa insulina. |
-
2018
- 2018-12-21 MX MX2020006658A patent/MX2020006658A/es unknown
- 2018-12-21 BR BR112020012268-8A patent/BR112020012268A2/pt not_active IP Right Cessation
- 2018-12-21 CN CN201880083343.5A patent/CN111565740A/zh active Pending
- 2018-12-21 EP EP18837063.9A patent/EP3727427A1/en active Pending
- 2018-12-21 AU AU2018388417A patent/AU2018388417C1/en active Active
- 2018-12-21 KR KR1020207020257A patent/KR20200103029A/ko not_active Ceased
- 2018-12-21 US US16/955,698 patent/US20210008170A1/en not_active Abandoned
- 2018-12-21 WO PCT/US2018/067294 patent/WO2019126753A1/en not_active Ceased
- 2018-12-21 JP JP2020534601A patent/JP2021506933A/ja active Pending
-
2023
- 2023-07-24 US US18/357,666 patent/US12514907B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021506933A (ja) | 2021-02-22 |
| US20210008170A1 (en) | 2021-01-14 |
| AU2018388417A1 (en) | 2020-07-02 |
| AU2018388417C1 (en) | 2025-07-10 |
| BR112020012268A2 (pt) | 2020-11-24 |
| CN111565740A (zh) | 2020-08-21 |
| WO2019126753A1 (en) | 2019-06-27 |
| KR20200103029A (ko) | 2020-09-01 |
| US12514907B2 (en) | 2026-01-06 |
| EP3727427A1 (en) | 2020-10-28 |
| US20240016898A1 (en) | 2024-01-18 |
| AU2018388417B2 (en) | 2025-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2017000426A1 (en) | Pharmaceutical compositions for combination therapy | |
| JOP20200156A1 (ar) | إيسكيتامين لعلاج الاكتئاب | |
| EA201590759A1 (ru) | Композиция для лечения диабета или диажирения, содержащая аналог оксинтомодулина | |
| MX2021004821A (es) | Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia. | |
| MX2019013279A (es) | Metodos de tratamiento del sindrome de doose utilizando fenfluramina. | |
| MX2017008569A (es) | Derivados de glucagon con estabilidad mejorada. | |
| PH12015502276A1 (en) | Therapeutic uses of empagliflozin | |
| PL385586A1 (pl) | Nowe analogi insuliny o przedłużonym działaniu | |
| MX2020013740A (es) | Uso de empagliflozina para el tratamiento de trastornos metabolicos, la prevencion, y para la reduccion del riesgo de sufrir o para retrasar la ocurrencia de un episodio cardiovascular. | |
| MX2020006658A (es) | Tratamiento de hipoglucemia inducida por el ejercicio en la diabetes tipo 1 y tipo 2 en la que se usa insulina. | |
| EA201691420A1 (ru) | Композиции енолазы 1 (eno1) и их применение | |
| RU2013132566A (ru) | Терапевтическое средство от грыжи межпозвоночного диска | |
| MX2020001342A (es) | Uso de gaboxadol en el tratamiento contra diabetes y afecciones relacionadas. | |
| PH12017500392A1 (en) | Medical treatments based on anamorelin | |
| BR112017024997A2 (pt) | tratamento de hipoglicemia pós-bariátrica com antagonistas de glp-1 | |
| MX2025003477A (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| MX2020000488A (es) | Metodos y composiciones para el tratamiento del dolor usando capsaicina. | |
| PH12015502465A1 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| MX2023001388A (es) | Agente terapéutico para lesiones nerviosas. | |
| FI20135503A7 (fi) | Kysteiini tai sen johdannainen atrofisen gastriitin hoitamiseen | |
| MX2022010628A (es) | Composicion para la prevencion y tratamiento de la disbiosis. | |
| EP4349402A3 (en) | Insulinotropic and glucagonotropic effects of beta-lactoglobulin | |
| CN104998224A (zh) | 治疗跌打扭伤的药物 | |
| ZA202202673B (en) | Methods and compositions for treating endometriosis | |
| Misery | Erythema and burns: 5 case report |